Suppr超能文献

喉癌根治性放疗中合并症评分和生活方式因素的影响。

Impact of comorbidity scores and lifestyle factors in curative radiotherapy in laryngeal cancer.

机构信息

Institute of Radiation Oncology, First Faculty of Medicine, Charles University and Bulovka University Hospital, Budinova 67/2, 18081, Prague, Czech Republic.

Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic.

出版信息

Strahlenther Onkol. 2023 Oct;199(10):881-890. doi: 10.1007/s00066-023-02072-y. Epub 2023 Apr 12.

Abstract

PURPOSE

The principal goal of treatment of laryngeal cancer is to eliminate a tumour while preserving laryngeal function with radio(chemo)therapy being the mainstay of treatment. The aim of this report is to present the influence of comorbidities and lifestyle factors on treatment outcomes in our cohort of patients.

METHODS

During the period 2009-2018, curative radio(chemo)therapy for laryngeal cancer was performed on 189 patients.

RESULTS

The median OS was 50.8 months, with a mean PFS of 96.5 months, mean LC of 101.4 months and a median follow-up of 38.1 months. Acute and late treatment toxicity grade 3-4 was observed in 39.2% patients and 10.1% patients, respectively. A significant effect on overall survival was confirmed for the baseline PS (performance status), severity of weight loss, baseline haemoglobin values, history of alcohol abuse, marital status and comorbidities according to the Charlson Comorbidity Index, as well as the ACE-27 and ASA scores.

CONCLUSIONS

In our cohort of patients treated with radio(chemo)therapy for laryngeal cancer, we found good therapeutic results and an acceptable side-effect profile. Statistically significant predictors of overall survival were the baseline PS, weight loss, anaemia, associated comorbidities, history of alcohol abuse and marital status.

摘要

目的

喉癌治疗的主要目标是在保留喉功能的同时消除肿瘤,放射(化疗)治疗是主要的治疗方法。本报告的目的是介绍合并症和生活方式因素对我们患者队列治疗结果的影响。

方法

在 2009 年至 2018 年期间,对 189 例喉癌患者进行了根治性放射(化疗)治疗。

结果

中位总生存期为 50.8 个月,平均无进展生存期为 96.5 个月,平均局部控制率为 101.4 个月,中位随访时间为 38.1 个月。39.2%的患者出现 3-4 级急性和迟发性治疗毒性,10.1%的患者出现 3-4 级急性和迟发性治疗毒性。根据 Charlson 合并症指数、ACE-27 和 ASA 评分,基线 PS(表现状态)、体重减轻程度、基线血红蛋白值、酒精滥用史、婚姻状况和合并症严重程度对总生存有显著影响。

结论

在我们接受放射(化疗)治疗的喉癌患者队列中,我们发现了良好的治疗效果和可接受的副作用谱。总生存率的统计学显著预测因子是基线 PS、体重减轻、贫血、合并症、酒精滥用史和婚姻状况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea19/10541830/37d0cc0164c5/66_2023_2072_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验